Explore free-to-access cardiology content, including expert video discussions, guideline-relevant analysis and peer-reviewed reviews designed for application in cardiovascular practice.
New Horizons in Dyslipidaemia 2026
On-Demand Video Event
With forthcoming updates anticipated at American College of Cardiology Annual Scientific Session, dyslipidaemia management is entering a period of refinement, particularly in relation to triglycerides, remnant cholesterol, LDL-C and lipoprotein(a).
In this on-demand symposium, under the leadership of course directors Dr Peter Libby, Prof Kausik Ray and Prof Erik Stroes, the faculty examine persistent residual risk despite LDL-C lowering, mechanistic insights into atherothrombosis, and the evolving role of combination lipid-lowering strategies. The discussion bridges clinical trial evidence with the implementation challenges encountered in routine care pathways.
Three Ways AI Will Change Your Practice
5-Minute Insight
Artificial intelligence is moving from experimental deployment to embedded infrastructure across health systems. In this short interview, we speak with Dr Robert Wachter, author of the newly published book A Giant Leap: How AI Is Transforming Healthcare and What That Means for Our Future.
The discussion takes a pragmatic lens, exploring how AI is reshaping administrative workload, expanding cognitive bandwidth, and influencing therapeutic selection in cardiology clinics and procedural settings.
Lifetime Benefits of Combination Therapy in HFpEF
5-Minute Insight
Heart failure with preserved ejection fraction (HFpEF) management is shifting from sequential escalation to early multidrug strategies. Dr Muthiah Vaduganathan synthesises cross-trial data evaluating early initiation of:
- SGLT2 inhibitors
- Non-steroidal mineralocorticoid receptor antagonists (nsMRAs)
- Angiotensin receptor–neprilysin inhibitors (ARNIs)
The analysis models cumulative event reduction and projected gains in event-free survival across HFmrEF and HFpEF populations, reframing therapy timing as a determinant of lifetime benefit rather than short-term relative risk reduction alone.
Parallax Substack: When Cardiometabolic Disease Becomes the Story
Cardiometabolic disease is increasingly central to the burden of ASCVD, HFpEF and CKD. In this discussion, Dr Ankur Kalra speaks with Prof Naveed Sattar to address pivotal clinical and translational questions.
The conversation explores patterns of risk clustering, shared pathophysiological mechanisms, and the implications for integrated, cross-specialty service design.
Essential Cardiology Reads for February
The following peer-reviewed articles provide clinically actionable updates spanning lipid biology, AF ablation strategy, device therapy, hypertrophic cardiomyopathy genetics and cardio-respiratory overlap syndromes.
Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis
A Filtz et al. European Cardiology Review
Published in European Cardiology Review, this review examines the pro-atherogenic and pro-thrombotic properties of lipoprotein(a), including:
- Apo(a)-mediated interference with fibrinolysis
- Oxidised phospholipid carriage
- Synergistic interaction with LDL particles
The article contextualises epidemiological risk data alongside emerging antisense and siRNA-based Lp(a)-lowering therapies, outlining implications for primary and secondary ASCVD prevention.
Uncharted Waters: The OCEAN Trial and the Expanding Indications for AF Ablation
JS Gill et al. European Cardiology Review
This analysis in European Cardiology Review reviews findings from OCEAN and ALONE-AF, focusing on post-ablation anticoagulation strategies.
The article details:
- Trial design and inclusion criteria
- Stroke and systemic embolism outcomes
- Bleeding risk considerations
- Scenarios where anticoagulation withdrawal may be considered
It emphasises careful patient selection and shared decision-making in the context of evolving ablation efficacy data.
Role of Device Therapy in Complementing Contemporary Medical Management
Y Benarroch et al. US Cardiology Review
In US Cardiology Review, this review evaluates how device therapy integrates with guideline-directed medical therapy (GDMT) in heart failure.
Key areas include:
- Indications for ICD and CRT in the era of quadruple therapy
- Timing of implantation relative to pharmacological optimisation
- Impact on hospitalisation, sudden cardiac death and functional status
The discussion reflects contemporary sequencing strategies rather than device-versus-drug framing.
Genetics in Hypertrophic Cardiomyopathy: An Evolving Clinical Landscape
MN Brögger et al. Cardiac Failure Review
Published in Cardiac Failure Review, this article outlines the expanding role of genetic testing in hypertrophic cardiomyopathy (HCM).
It addresses:
- Indications for genetic testing
- Interpretation of pathogenic versus variant-of-uncertain-significance results
- Cascade screening in first-degree relatives
- Integration of genotype into risk stratification
The review also explores how gene-targeted and myosin-modulating therapies may influence future HCM care pathways.
Prevalence of HFpEF in Patients Living with COPD
NA Wahid et al. Journal of Asian Pacific Society of Cardiology
This study in the Journal of Asian Pacific Society of Cardiology evaluates the frequency of HFpEF among patients with chronic obstructive pulmonary disease (COPD).
Key findings highlight:
- Substantial under-recognition of HFpEF in respiratory clinics
- The diagnostic contribution of structured echocardiographic assessment
- Implications for dyspnoea evaluation and integrated cardio-respiratory care
The paper reinforces the need for systematic screening approaches in multimorbid populations.
All featured content is editorially independent, free to access and developed for cardiovascular professionals.